Article Text

Download PDFPDF
The severity of phenotype linked to SUCLG1 mutations could be correlated with residual amount of SUCLG1 protein
  1. C Rouzier1,2,
  2. S Le Guédard-Méreuze3,
  3. K Fragaki1,2,
  4. V Serre4,
  5. J Miro3,
  6. S Tuffery-Giraud3,
  7. A Chaussenot1,
  8. S Bannwarth1,2,
  9. C Caruba5,
  10. E Ostergaard6,
  11. J-F Pellissier7,
  12. C Richelme8,
  13. C Espil9,
  14. B Chabrol10,
  15. V Paquis-Flucklinger1,2
  1. 1Department of Medical Genetics, Archet 2 Hospital, CHU of Nice France
  2. 2IGMRC, FRE CNRS / UNSA 3086, Nice Sophia-Antipolis University, Nice, France
  3. 3Université Montpellier 1, UFR Médecine, Montpellier, France
  4. 4INSERM U781, Necker Enfants Malades Hospital, Paris, France
  5. 5Department of Biochemistry, Pasteur Hospital, CHU of Nice, France
  6. 6Department of Clinical Genetics, National University Hospital Rigshospitalet, Copenhagen, Denmark
  7. 7Department of Neuropathology, Timone Hospital, CHU of Marseille, France
  8. 8Department of Pediatrics, Archet 2 Hospital, CHU of Nice, France
  9. 9Department of Neuropediatrics, CHU Pellegrin, Bordeaux, France
  10. 10Department of Neuropediatrics, Timone Hospital, CHU of Marseille, France
  1. Correspondence to Professor V Paquis-Flucklinger, IGMRC, FRE CNRS / UNSA 3086, Medicine School, 28 av de Valombrose 06107, Nice cedex 2, France; paquis{at}


Background Succinate-CoA ligase deficiency is responsible for encephalomyopathy with mitochondrial DNA depletion and mild methylmalonic aciduria. Mutations in SUCLA2, the gene encoding a β subunit of succinate-CoA ligase, have been reported in 17 patients until now. Mutations in SUCLG1, encoding the α subunit of the enzyme, have been described in two pedigrees only.

Methods and findings In this study, two unrelated patients harbouring three novel pathogenic mutations in SUCLG1 were reported. The first patient had a severe disease at birth. He was compound heterozygous for a missense mutation (p.Pro170Arg) and a c.97+3G>C mutation, which leads to the complete skipping of exon 1 in a minigene expression system. The involvement of SUCLG1 was confirmed by western blot analysis, which showed absence of SUCLG1 protein in fibroblasts. The second patient has a milder phenotype, similar to that of patients with SUCLA2 mutations, and is still alive at 12 years of age. Western blot analysis showed some residual SUCLG1 protein in patient's fibroblasts.

Conclusions Our results suggest that SUCLG1 mutations that lead to complete absence of SUCLG1 protein are responsible for a very severe disorder with antenatal manifestations, whereas a SUCLA2-like phenotype is found in patients with residual SUCLG1 protein. Furthermore, it is shown that in the absence of SUCLG1 protein, no SUCLA2 protein is found in fibroblasts by western blot analysis. This result is consistent with a degradation of SUCLA2 when its heterodimer partner, SUCLG1, is absent.

  • Respiratory chain defect
  • mtDNA depletion
  • methylmalonic aciduria
  • SUCLG1 mutation
  • minigene expression system
  • metabolic disorders

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests None.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.